TrialInvestigational new drugs2005

A phase II study of sabarubicin (MEN-10755) as second line therapy in patients with locally advanced or metastatic platinum/taxane resistant ovarian cancer.

Francesco Caponigro et al.PubMed ↗Publisher ↗

No numbers read from the abstract.